|
[Related PubMed/MEDLINE]
Total Number of Papers: 111
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
CircRNA WHSC1 targets the miR-646/NPM1 pathway to promote the development of endometrial cancer. |
circRNAs |
| 2 |
2020 |
Clinicopathological significance of common genetic alterations in patients with acute promyelocytic leukemia. |
AML, APL, bcr1, EGFR, FLT3, PCR, PML, WBC |
| 3 |
2020 |
EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53. |
ALCL, EBP2, NPM-ALK |
| 4 |
2020 |
Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience. |
AML, HRM PCR, MFI |
| 5 |
2020 |
Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1. |
Ad, ViPR |
| 6 |
2020 |
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. |
ALCL, ALK, CRISPR, IL10RA |
| 7 |
2020 |
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. |
MLL1 |
| 8 |
2020 |
Modulation of Amyloidogenic Peptide Aggregation by Photoactivatable CO-Releasing Ruthenium(II) Complexes. |
ThT |
| 9 |
2020 |
Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). |
AML, CEBPA, CI, CIR, CSF3R, FLT3-ITD, HR, MRD |
| 10 |
2020 |
NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. |
AML, CBS, CTCF, NES |
| 11 |
2020 |
Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma. |
18F-FDG, MTV, PET/CT, TLG |
| 12 |
2020 |
Proteostasis unbalance of nucleophosmin 1 in Acute Myeloid Leukemia: An aggregomic perspective. |
AML |
| 13 |
2020 |
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. |
AML, CR, CRi, FLT3, HSCT, LFS, OME, OS, R/R, SOME, VAF |
| 14 |
2020 |
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. |
AML, ITD |
| 15 |
2019 |
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations. |
AML, BCR-ABL |
| 16 |
2019 |
Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60years. |
allo-HSCT, AML, CEBPA, HR, OS, PRT |
| 17 |
2019 |
Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. |
AML, FLT3 |
| 18 |
2019 |
Cellular therapy against public neoantigens. |
AMLs |
| 19 |
2019 |
Cellular Zinc Finger Protein 622 Hinders Human Adenovirus Lytic Growth and Limits Binding of the Viral pVII Protein to Virus DNA. |
HAdV, HAdVs, ZNF622 |
| 20 |
2019 |
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. |
--- |
| 21 |
2019 |
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. |
AML, FLT3, ITD |
| 22 |
2019 |
Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. |
MRD, UMI |
| 23 |
2019 |
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. |
AML, NPM1mut, pts, tAML, WES |
| 24 |
2019 |
Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. |
CBM, ETP-ALL |
| 25 |
2019 |
Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. |
AML, CN, FLT3, PCR |
| 26 |
2019 |
Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia. |
AML, DNMT3A, FLT3, HRM, ITD, TKD |
| 27 |
2019 |
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. |
AML, TCR |
| 28 |
2019 |
Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? |
AML, HLA, MS |
| 29 |
2019 |
NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. |
AML, FLT3, STAT5, TKD |
| 30 |
2019 |
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study. |
AML, FLT3, OS, PML-RARA |
| 31 |
2019 |
The acute myeloid leukemia-associated Nucleophosmin 1 gene mutations dictate amyloidogenicity of the C-terminal domain. |
AML, SEM |
| 32 |
2019 |
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. |
Adv, AML, AR, ELN, fav, FLT3, IA, INT, IR |
| 33 |
2019 |
[Expression of WT1 gene and its prognostic value in patients with acute myeloid leukemia]. |
AML, DFS, FLT3-ITD, ORR, OS, WT1 |
| 34 |
2018 |
Acute Myeloid Leukemia: Is That All There Is? |
AML, CEBPalpha, CPI, FLT3, LSD1, MRD, NF-kappaB |
| 35 |
2018 |
Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. |
Cbl, CEBPA, JAK2, KRAS, TET2 |
| 36 |
2018 |
Establishment of a Multiplex PCR-Based Procedure for Detection of Most Common Mutations in NPM1, FLT3 in Acute Myeloid Leukemia Patients. |
AML, FLT3 |
| 37 |
2018 |
Glycogen synthase kinase-3 and alternative splicing. |
GSK-3 |
| 38 |
2018 |
Long noncoding RNA HOTAIR mediates the estrogen-induced metastasis of endometrial cancer cells via the miR-646/NPM1 axis. |
EC, HOX |
| 39 |
2018 |
NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. |
AML, CN-AML, PCR |
| 40 |
2018 |
Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India. |
AML, EGFR, FLT3 |
| 41 |
2018 |
When the good go bad: Mutant NPM1 in acute myeloid leukemia. |
AML, NK |
| 42 |
2018 |
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: AHokkaido Leukemia Net Study. |
AML, CEBPA, CN, FLT3-ITD, SNP, WT1 |
| 43 |
2017 |
A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest. |
CRBN, MM |
| 44 |
2017 |
Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. |
AML, CN, HVs |
| 45 |
2017 |
Cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-beta signaling. |
CUG2, EMT |
| 46 |
2017 |
FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. |
CN-AML, FLT3 |
| 47 |
2017 |
Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. |
AML, PI, wt-NPM1 |
| 48 |
2017 |
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. |
CLL, RNPs, siRNA |
| 49 |
2017 |
NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells. |
AML, PML |
| 50 |
2017 |
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. |
--- |
| 51 |
2017 |
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. |
AML, ECM, NET, SPARC |
| 52 |
2017 |
Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. |
AML, CEBPA, FLT3, IDH1, LKB1 |
| 53 |
2016 |
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. |
--- |
| 54 |
2016 |
Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. |
AML, AVA, CRM1, FLT3, WT |
| 55 |
2016 |
Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. |
AML, MFC, MRD, RQ-PCR |
| 56 |
2016 |
Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission. |
allo-HSCT, AML, CR, EFS, MRD, OS |
| 57 |
2016 |
Regulation of Neuronal Survival by Nucleophosmin 1 (NPM1) Is Dependent on Its Expression Level, Subcellular Localization, and Oligomerization Status. |
CDKs |
| 58 |
2016 |
Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. |
HMG, SOX6 |
| 59 |
2016 |
The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b. |
AML, NPM1-mA |
| 60 |
2016 |
The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia. |
AML, CIR, FLT3-ITD, HR, NK, OS, SNP, WT1 |
| 61 |
2016 |
Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. |
AA, AUC, BPH, EA, PCa, PSA, ROC, SERPA, TAAs |
| 62 |
2015 |
1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). |
--- |
| 63 |
2015 |
A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. |
MM, TRAP |
| 64 |
2015 |
Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. |
AML |
| 65 |
2015 |
ATRA and ATO team up against NPM1. |
Abl, AML, APL, ATO, ATRA, bcr |
| 66 |
2015 |
Coexpression Pattern Analysis of NPM1-Associated Genes in Chronic Myelogenous Leukemia. |
CML |
| 67 |
2015 |
Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. |
AML, PB, PCR |
| 68 |
2015 |
Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. |
AML |
| 69 |
2015 |
Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia. |
CML |
| 70 |
2015 |
Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. |
allo, CN-AML, FLT3-ITD, HSCT, OS |
| 71 |
2015 |
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. |
AML, PML, RA |
| 72 |
2014 |
Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. |
RT-qPCR |
| 73 |
2014 |
Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-alpha signaling. |
ERalpha |
| 74 |
2014 |
FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India. |
AML, APL, FLT3 |
| 75 |
2014 |
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. |
AMLs, APE1, BER |
| 76 |
2014 |
High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. |
AML, EFS, FLT3, FLT3-ITD, FLT3-TKD, HRM |
| 77 |
2014 |
Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. |
CN-AML |
| 78 |
2014 |
Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. |
AML, DFS, HR, NPM1-mt, NPM1-wt |
| 79 |
2014 |
Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. |
DSB, MEFs, NSCLC, TMA |
| 80 |
2014 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. |
VPA |
| 81 |
2013 |
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. |
AML, CNAs, DNMT3Amut, NPM1mut, UPDs |
| 82 |
2013 |
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. |
AML, CN-AML, FACS, NK, RQ-PCR |
| 83 |
2013 |
Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia. |
AML, IHC |
| 84 |
2013 |
Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). |
allo-HCT, AML, CN-AML, HCT |
| 85 |
2013 |
Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. |
CRC |
| 86 |
2013 |
Prognostic Impact of Nucleophosmin 1 (NPM1) Gene Mutations in Egyptian Acute Myeloid Leukemia Patients. |
PCR-SSCP |
| 87 |
2013 |
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. |
allo-SCT, AML, OS |
| 88 |
2013 |
[Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis]. |
AML, CE, FLT3 |
| 89 |
2012 |
Acute myeloid leukemia and transcription factors: role of erythroid Kruppel-like factor (EKLF). |
AML, CEBPA, EFS, EKLF, FLT3, GATA1, GATA2, OS |
| 90 |
2012 |
Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. |
AML, FLT3, WBC |
| 91 |
2012 |
miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. |
AML, LNA, NPM1mut |
| 92 |
2011 |
Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. |
qPCR |
| 93 |
2011 |
Gene expression profiling in acute myeloid leukaemia. |
AML, CEBPA, FAB classification, FLT3-ITD, WHO |
| 94 |
2011 |
miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. |
AML, IR, MDM4, miRNA |
| 95 |
2011 |
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. |
ATRA |
| 96 |
2010 |
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. |
AML |
| 97 |
2010 |
Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line. |
--- |
| 98 |
2010 |
Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). |
AML, LDH, TLC |
| 99 |
2010 |
High cytogenetic or molecular genetic risk acute myeloid leukemia. |
FLT3, ITD |
| 100 |
2010 |
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. |
AML, CEBPA, CN-AML, CNAs, SNP, UPD |
|
A Search Service for Abbreviation / Long Form
